Over the past decade, efforts have focused on the connection between mitochondrial activity and the etiology of obesity, insulin resistance and the progression of type 2 diabetes mellitus (T2DM) 1,2 . Numerous studies have shown that metabolic disorders are accompanied by reduced mitochondrial content, compromised mitochondrial respiratory capacity, heightened oxidative stress and, consequently, altered whole-body lipid and glucose metabolism 3, 4 . The mechanisms that prompt the compromised mitochondrial activity in obesity-driven T2DM and how targeting these processes can improve metabolic profiles remain largely unknown. New preclinical models that elucidate a role for mitochondria in cellular homeostasis have the potential to shed new light on these issues and will allow the discovery of improved therapeutic avenues.
Over the past decade, efforts have focused on the connection between mitochondrial activity and the etiology of obesity, insulin resistance and the progression of type 2 diabetes mellitus (T2DM) 1, 2 . Numerous studies have shown that metabolic disorders are accompanied by reduced mitochondrial content, compromised mitochondrial respiratory capacity, heightened oxidative stress and, consequently, altered whole-body lipid and glucose metabolism 3, 4 . The mechanisms that prompt the compromised mitochondrial activity in obesity-driven T2DM and how targeting these processes can improve metabolic profiles remain largely unknown. New preclinical models that elucidate a role for mitochondria in cellular homeostasis have the potential to shed new light on these issues and will allow the discovery of improved therapeutic avenues.
The expansion of healthy adipose tissue has potent antidiabetic effects because it provides a 'safe haven' to neutralize and store excess free fatty acids (FFAs) that would otherwise cause toxicity to other, more sensitive organs that regulate whole-body metabolism. Thus, the inability to appropriately expand subcutaneous white adipose tissue (sWAT) may underlie the development of insulin resistance, β cell failure and T2DM 5 . In addition to storing excess lipids, however, adipocytes can also secrete adipokines that help buffer the lipotoxic side effects of excess caloric intake. A crucial player in this regard is adiponectin. Secreted exclusively from adipocytes, adiponectin promotes the preferential storage of triglycerides in adipose tissue 5, 6 to improve metabolic flexibility. Adiponectin further reduces the accumulation of ceramide species to improve cellular survival and insulin sensitivity. Mice overexpressing adiponectin in an ob/ob background have improved insulin sensitivity and lipid profiles compared to ob/ob mice that have normal obesity-associated downregulation of adiponectin 5 . Such characteristics are attributed to augmented ceramidase activity 7 , a redistribution of lipids and higher adipogenesis concomitant with gross sWAT expansion 5, 6 . However, the underlying mechanisms that initiate this paradoxical phenomenon of lipid redistribution and chronic adipose tissue expansion to improve metabolic health are not fully defined.
Mitochondria have a central role in energy homeostasis by partitioning fuels toward β-oxidation or storage as fat. During adipose tissue expansion, the oxidation of lipid and carbohydrate fuels requires the coordinated regulation of downstream metabolic pathways such as the tricarboxylic acid cycle and the electron transport chain (ETC). Compromised mitochondrial energy production is a major anomaly in obesity. In particular, obese individuals and those with type 2 diabetes are known to have lower β-oxidation rates, lower oxidative enzymatic activities and lower ETC activity 8, 9 together with greater glycolytic capacities and higher uptake of cellular fatty acids compared to nonobese and nondiabetic individuals 10 . Although these observations highlight oxidative failure during lipid accumulation, the mechanisms by which diminished β-oxidation and suboptimal mitochondrial function stimulate lipid uptake and accumulation in obesity have not been fully established.
Here we take advantage of the unique properties of the mitochondrial membrane protein mitoNEET. Using gain-of-function and loss-of-function models for mitoNEET, we induced chronic and massive adipose tissue expansion, at least partially through an upregulation of adiponectin production and release from adipocytes. MitoNEET achieves these effects through selective modulation of mitochondrial electron transport activity. This establishes a tight functional connection between mitoNEET, mitochondrial activity and adiponectin release.
Originally, mitoNEET was identified as a unique dimeric mitochondrial membrane target crosslinked to the thiazolidinedione (TZD) pioglitazone 11, 12 . Located in the outer mitochondrial membrane, mitoNEET was named according to its C-terminal amino acid sequence, AsnGluGluThr (NEET) 11 . Furthermore, oriented toward the cytoplasm, the CDGSH domain of mitoNEET can bind redoxactive, pH-labile clusters made up of two iron ions and two sulfur ions (2Fe-2S clusters) [13] [14] [15] , with pioglitazone having been reported to stabilize the protein against 2Fe-2S cluster release 12 . MitoNEET achieves its effects on cellular and systemic metabolic homeostasis by acting as a powerful regulator of mitochondrial iron content. We used these properties to influence mitochondrial bioenergetics and metabolism in a tissue-type-and cell-type-specific manner, resulting in alterations in whole-body energy homeostasis and, further, opening up new avenues for cell-specific manipulation of mitochondrial activity in any cell type.
RESULTS

MitoNEET promotes gross adipose tissue expansion
Mice can be metabolically challenged by either introducing specific genetic mutations or providing them with a high-fat diet (HFD). An examination of tissues from mice exposed to HFD revealed that their expression of the mitochondrial protein mitoNEET is markedly lower in adipose tissue and the liver compared to its expression in these tissues in mice fed a standard chow diet (Fig. 1a) , indicating that altered mitoNEET expression may be a hallmark of metabolically challenged tissues.
To address more directly whether mitoNEET activity has a pertinent role in adipose tissue function, we used the 5.4-kb aP2 promoter 16 , an isoprostane derived from arachidonic acid through in vivo lipid peroxidation that serves as a measure of oxidative stress) in FVB female ob/ob and MitoN-Tg ob/ob sWAT (n = 5 mice per group). *P < 0.05, **P < 0.01, ***P < 0.001 by Student's t test. All data shown are means ± s.e.m. npg generate an adipose-specific transgenic mouse model of mitoNEET overexpression (MitoN-Tg mice) (Fig. 1b) . This led to the overexpression of mitoNEET within a physiological range (approximately fivefold overexpression in sWAT, with lower expression in other fat pads). Notably, expression of the transgene was limited to the adipocytes and was not present in other cell types, including macrophages (data not shown).
To assess the extent to which mitoNEET action can affect adipose tissue expansion, we applied a more prolonged metabolic challenge. We wanted to determine how maintaining elevated expression of mitoNEET during adipose tissue expansion affects the cellular physiology of a mouse with a diabetic phenotype. We therefore generated ob/ob mice in a FVB background harboring the adipose-specific mitoNEET overexpression cassette. Both male and female MitoN-Tg ob/ob mice gained substantially more body weight than their nontransgenic ob/ob littermates (Fig. 1c) , with the heaviest female MitoN-Tg ob/ob mouse having a body weight of 129.5 g (Fig. 1d) . Despite their body weight, male and female MitoN-Tg ob/ob mice had euglycemic blood glucose concentrations, whereas their nontransgenic ob/ob counterparts had diabetic hyperglycemic concentrations (male ob/ob mice: 474 ± 26 mg dl −1 (mean ± s.e.m.); male MitoN-Tg ob/ob mice: 111 ± 14 mg dl −1 , P < 0.001; female ob/ob mice: 411 ± 19 mg dl −1 ; female MitoN-Tg ob/ob mice: 123 ± 6 mg dl −1 , P < 0.001) (Fig. 1e ). An oral glucose tolerance test (OGTT) on these morbidly obese transgenic mice revealed a profile that was comparable to that of fully glucose-tolerant wildtype (WT) mice despite using an oral glucose dose that was based on body weight (that is, the transgenic mice received a three to four times higher glucose load than the WT mice) (Fig. 1f) . In hyperinsulinemiceuglycemic clamp studies, MitoN-Tg ob/ob mice required a significantly higher glucose infusion rate than nontransgenic ob/ob mice (P < 0.01, n = 5 mice per group) (Fig. 1g) , implicating a higher whole-body insulin sensitivity in the transgenic mice. Hepatic insulin sensitivity was also enhanced in MitoN-Tg ob/ob mice, as shown by a markedly lower hepatic glucose output than nontransgenic ob/ob mice (Fig. 1g) . Consistent with the improved carbohydrate metabolism, the histology of the liver, adipose tissue and pancreas were normalized in MitoN-Tg ob/ob mice compared to nontransgenic ob/ob mice, with negligible hepatic lipid accumulation (Fig. 1h) . A normalization of adipocyte cell size was also apparent in the MitoN-Tg ob/ob mice, concomitant with limited sWAT immune-cell infiltration (Fig. 1h) . Moreover, MitoN-Tg ob/ob mice retained the same number and morphology of islets as a WT mouse, whereas diabetic ob/ob mice retained less than half the number of islets of WT mice (WT: 32 ± 2 islets (mean ± s.e.m.); ob/ob: 14 ± 6 islets; MitoN-Tg ob/ob: 38 ± 2 islets). Furthermore, we found markedly less fibrosis in MitoN-Tg ob/ob mice than in their nontransgenic ob/ob counterparts, primarily evident in the sWAT, as determined by trichrome staining (Fig. 1h) .
Ceramides are a group of sphingolipids that are frequently associated with insulin resistance 17 ; consistent with this, MitoN-Tg ob/ob mice had significantly lower concentrations of hepatic ceramides than nontransgenic ob/ob mice (P < 0.05, n = 4 mice per group) (Fig. 1i) . Similarly, diacylglycerols are another class of lipids that, when elevated in the liver, have been implicated in reduced cellular insulin responses 18 . Notably, MitoN-Tg ob/ob mice had markedly lower hepatic diacylglycerol concentrations than nontransgenic ob/ob mice (ob/ob: 1,644.9 ± 180.3 pmol mg −1 (mean ± s.e.m.); MitoN-Tg ob/ob: 936.8 ± 97.5 pmol mg −1 ; P < 0.05), further suggesting an improved hepatic lipid profile.
After an oral gavage of 20% intralipid, we examined F2-isoprostane concentrations as a measure of reactive oxygen species (ROS)-driven lipid peroxidation 19 . Notably, MitoN-Tg ob/ob sWAT harbors markedly fewer ROS-induced lipid peroxidation products than ob/ob sWAT (Fig. 1j) , showing a paradoxical low degree of oxidative stress in a morbidly obese setting. We found similar results in MitoN-Tg mice exposed to HFD in the absence of the ob/ob mutation (data not shown). In addition, we were able to initiate similar fat-pad expansion by directly infecting the sWAT of WT mice with a mitoNEET-expressing adeno-associated virus (AAV), which prompted a local threefold overexpression of mitoNEET compared to injection of a control virus into the collateral fat pad (data not shown). Collectively, these data indicate that overexpression of mitoNEET can promote adipose tissue expansion under multiple different conditions, such as HFD and loss of leptin expression, using various approaches for overexpression.
MitoNEET-enhanced lipid uptake and adiponectin production Younger mice carrying the mitoNEET transgene in a WT background that are maintained on a chow diet have no considerable differences in body weight or insulin sensitivity when compared to WT mice (data not shown). We proposed that an unchallenged setting would be an ideal condition to evaluate the MitoN-Tg sWAT gene expression profile in more detail, as we would not have the additional confounders of chronic obesity and insulin resistance, which alter the microarray profile secondary to the initial transcriptional changes. The main transcriptional fingerprints that were substantially altered in sWAT by mitoNEET overexpression are listed in Supplementary  Table 1 . The gene regulatory pathways that were markedly altered in response to mitoNEET induction were adipogenesis, triglyceride synthesis, nonesterified fatty acid re-esterification, fatty acid biosynthesis, lipid-droplet-associated protein synthesis, fatty acid uptake, fatty acid transport and glucose uptake (Supplementary Table 1) ; we confirmed these changes using RT-PCR analysis ( Fig. 2a and Supplementary Fig. 1 ). Supplementary Table 2 shows a list of the RT-PCR primer sequences of differentially expressed genes that we identified in the microarray cluster analysis of sWAT derived from WT and MitoN-Tg mice. Notably, we found a marked upregulation of the fatty acid transporter protein Cd36 in MitoN-Tg sWAT when compared with WT sWAT, suggesting that mitoNEET action may alter the kinetics of cellular lipid uptake. Indeed, a triglyceride clearance test revealed a striking efficacy in the rate of lipid clearance in MitoN-Tg mice. Although the WT mice had the expected hyperlipidemic excursion of triglyceride after exposure to an oral lipid gavage, MitoN-Tg mice had a significantly higher rate of triglyceride clearance (P < 0.01, n = 6 mice per group) (Fig. 2b) .
The ability of MitoN-Tg mice to rapidly dispose of exogenous lipids, coupled with the long-term ability to enhance fat-mass expansion, is a phenotype reminiscent of that of adiponectinoverexpressing mice 5 . The transcriptional upregulation of adiponectin that we observed in the MitoN-Tg mice (Fig. 2a) is consistent with a potential involvement of adiponectin in the upregulation process of enhanced lipid storage in adipocytes. Indeed, MitoN-Tg mice had markedly higher circulating concentrations of adiponectin than WT mice (Supplementary Table 3) , with a prominently higher amount of the high-molecular-weight form of adiponectin (data not shown), highlighting the ability of mitoNEET to exert a constitutive stimulatory effect on adiponectin production and release. A similar effect on adiponectin upregulation is also observed in MitoN-Tg ob/ob mice when compared with nontransgenic ob/ob mice (Supplementary Table 4 ). The marked upregulation of adiponectin protein expression (Fig. 2c) was only evident in transgenic sWAT and was not apparent npg a r t i c l e s 1 5 4 2 VOLUME 18 | NUMBER 10 | OCTOBER 2012 nature medicine in gonadal WAT (gWAT), suggesting that local mitoNEET levels within a fat pad govern adiponectin production. Indeed, we found that adiponectin expression showed a tight positive correlation with how much mitoNEET was expressed within a given fat pad (Fig. 2d) . Given this result, we examined whether mitoNEET-enhanced lipid clearance is mediated directly through adiponectin upregulation. MitoN-Tg adiponectin knockout mice had significantly lower rates of triglyceride clearance than MitoN-Tg mice (P < 0.05, n = 6 mice per group) ( Fig. 2e) , suggesting that augmented lipid uptake is at least partially dependent on a mitoNEET-adiponectin axis. Whereas no differences were apparent between WT mice and MitoN-Tg mice in terms of systemic glucose and insulin concentrations under chow-fed conditions (Supplementary Table 3 ), we did find elevated systemic FFA and glycerol concentrations in MitoN-Tg mice after fasting them for 24 h (Supplementary Table 3 ), suggesting that mitoNEET concentration in adipocytes may influence fastinginduced lipolysis. In response to extracellular stimuli by catecholamines, adipocytes hydrolyze stored neutral triglycerides to liberate FFAs and glycerol 20 . Notably, after stimulation with β-3 adrenergic agonist, MitoN-Tg mice released considerably more glycerol than WT mice (Fig. 2f) , a phenotype also similar to that of adiponectin transgenic mice 21 . However, FFA release is massively substoichiometric to glycerol release. Thus, whereas we theoretically expected 3 moles of FFA to be released for every mole of glycerol released (a ratio that is usually closer to 2:1 in WT mice), we found less than 0.3 moles of FFAs liberated per mole of glycerol in the transgenic mice. This suggests that an extremely efficient re-esterification of FFAs to triglyceride occurs in these mice, along with an excess local pool of glycerol. Such a phenomenon is particularly apparent in an ob/ob setting, where the profound reduction in FFA efflux becomes problematic after fasting, a condition under which glucose concentrations rapidly achieve hypoglycemic levels (data not shown).
Phosphoenolpyruvate carboxykinase (Pepck) has a pertinent role in maintaining the homeostasis of FFA re-esterification in adipose tissue 22 , particularly through glyceroneogenesis 23 . The marked upregulation in Pepck expression in MitoN-Tg sWAT ( Supplementary  Fig. 1 ) suggests a mitoNEET-induced Pepck-dependent stimulation of glyceroneogenic pathways, which may effectively promote FFA re-esterification into the triglyceride pool within adipocytes. In addition, β-3 adrenergic stimulation of WAT is known to trigger the rapid release of insulin from pancreatic β cells 19 . After injection of the β-3 adrenoceptor agonist, we found a sharp rise in insulin concentrations accompanied by severe hypoglycemia in transgenic mice (data not shown), suggesting a fully functional and highly active adipo-insular axis in transgenic mice.
Lipoprotein lipase (LPL) has a key role in the clearance of circulating triglycerides and their routing toward either storage or oxidative tissues. MitoN-Tg sWAT has significantly more local LPL activity than WT sWAT (WT sWAT: 14.6 ± 3.5 µUg −1 h −1 (mean ± s.e.m.); MitoN-Tg sWAT: 25.7 ± 3.7 µUg −1 h −1 ; P < 0.001), with no (g) LPL activity in WT and MitoN-Tg sWAT and gWAT (n = 5 mice per group). *P < 0.05, **P < 0.01, ***P < 0.001. A Student's t test was used to determine P values. All data are means ± s.e.m.
npg differences in local LPL activity between MitoN-Tg and WT gWAT fat pads (Fig. 2g) . These data indicate an exceptionally responsive subcutaneous fat pad in the transgenic mice, a phenotype that is crucially dependent on, and directly proportional to, the local overexpression of mitoNEET.
MitoNEET-mediated effects on fatty acid metabolism To further tie mitoNEET expression to fatty acid metabolism, we injected a 3 H-triolein tracer into MitoN-Tg mice and WT mice to quantitatively assess lipid storage and β-oxidation rates. We found that MitoN-Tg mice had a significantly higher (235%; P < 0.001) rate of whole-body 3 H-triolein clearance than WT mice (Fig. 3a) , with sWAT being primarily responsible for the bulk of the differential (Fig. 3b ) of all the tissues examined ( Supplementary  Fig. 2a ). Considering that sWAT is the primary site of mitoNEET overexpression, the higher expression of mitoNEET locally within subcutaneous adipocytes is probably the direct mediator of these effects on lipid clearance. In parallel, we noted markedly lower β-oxidation rates in MitoN-Tg than WT sWAT and brown adipose tissue (BAT) (BAT being a secondary site of mitoNEET overexpression) ( Fig. 3c and Supplementary Fig. 2b ). Quantitatively, MitoN-Tg sWAT and BAT were substantially larger than WT sWAT and BAT (Fig. 3d) , consistent with a tight link to local overexpression of mitoNEET within these fat pads. Visually, MitoN-Tg sWAT appeared darker in color than WT sWAT (Fig. 3e) . Conversely, and presumably compensatory to sWAT hyperproliferation, MitoN-Tg gWAT and mesenteric WAT (mWAT) fat pads were markedly smaller than WT gWAT and mWAT fat pads (Fig. 3d,e and Supplementary Fig. 2c ). These observations suggest that by manipulating mitoNEET expression differentially in various fat pads, we can disrupt the steady-state distribution of lipid storage, thereby preferentially redistributing lipids toward fat pads enriched for mitoNEET. A qualitative histological examination of adipose tissue revealed that the adipocytes are smaller in MitoN-Tg sWAT than in WT sWAT (Fig. 3f) , indicating that within a mitoNEET-enriched environment, healthy adipose tissue expansion through adipocyte hyperplasia prevails rather than the metabolically unfavorable adipocyte hypertrophic expansion that is typically observed in states of obesityassociated insulin resistance 24 . In addition, MitoN-Tg gWAT adipocytes are smaller than WT gWAT adipocytes (Fig. 3f) , suggesting a diversion of lipids away from this fat pad to avoid formation of hypertrophic adipocytes.
MitoNEET modulates mitochondrial function and iron content
Previous reports have established mitoNEET as an outer mitochondrial membrane protein. Although the phenotypic changes associated with the alteration of mitoNEET expression are robust, the question arises of how an outer mitochondrial membrane protein exerts such profound effects on β-oxidation rates. MitoNEET can serve as an ironsulfur-cluster transfer protein 25 ; however, the physiological relevance of these clusters is unknown-they may have a role in mitochondrial iron metabolism. Indeed, we found that mitoNEET overexpression at the level of the mitochondrion results in an adipocyte mitochondrial iron metabolism that is markedly out of balance. More specifically, MitoN-Tg sWAT mitochondria contain significantly lower concentrations of iron than WT sWAT mitochondria (P < 0.001, n = 7 sWAT per group) (Fig. 4a) . This almost 50% lower concentration of mitochondrial iron suggests a crucial involvement of mitoNEET in supplying the components of the ETC with iron, a rate-limiting component for ETC activity 26 . Furthermore, we noted markedly lower heme iron concentrations in MitoN-Tg than WT sWAT mitochondria (data not shown); as mitochondrial heme synthesis and iron-sulfur-cluster metabolism are tightly linked processes 27 , this further highlights mitoNEET-induced alterations in iron homeostasis. Moreover, when assessing either WT mice fed a high-iron diet or mice with hemochromatosis (induced with targeted deletion of the Hfe gene, which leads to defects in iron handling and a cellular iron overload) 28 , we found that the total expression of mitoNEET was considerably upregulated (Fig. 4b) in both groups, with a notable stabilization of an SDS-resistant mitoNEET dimer. These results could be consistent with a counter-regulatory upregulation of mitoNEET under conditions of excess iron in an attempt to curb the additional transport of iron into the mitochondrial matrix under conditions of iron overload.
To address how mitoNEET lowers β-oxidation and promotes lipid accumulation, we examined the adipocyte overexpression model further. When examining the mitochondrial membrane potential (∆Ψm), 3T3-L1 preadipocytes stably transfected with either high or low concentrations of mitoNEET had a low ∆Ψm compared to cells transfected with a control plasmid (Fig. 4c) ; a similar reduction in ∆Ψm occurred as a result of treatment with TZD (Fig. 4c) . This mitoNEET-induced reduction in ∆Ψm may reflect insufficient ETC activity 29 , inefficient substrate supply to the mitochondria or an increased proton flux back into the To directly establish whether mitoNEET alters ETC activity, we performed electron-flow analyses and assessed oxygen-consumption rates (OCRs), a method that was previously established to assess mitochondrial function 30 . Of note, such OCR measurements are performed in the presence of the chemical uncoupler carbonyl cyanide 4 (trifluoromethoxy)phenylhydrazone (FCCP). MitoN-Tg sWAT mitochondria have markedly lower OCRs in response to the substrates pyruvate, malate, succinate and ascorbate than do WT sWAT mitochondria (Fig. 4d) . However, MitoN-Tg sWAT mitochondria have markedly higher OCRs in response to the complex I inhibitor rotenone (Fig. 4d) . Rotenone can promote ROS-induced oxidative stress 31 ; therefore, an ineffective inhibition of complex I by rotenone in MitoN-Tg mitochondria suggests that an indirect interference by mitoNEET may minimize ROS-driven damage. Moreover, we found that MitoN-Tg sWAT has a significantly lower ratio of NAD + to NADH than WT sWAT (P < 0.001, n = 5) (Fig. 4e) . This buildup of reduced NADH equivalents in MitoN-Tg sWAT suggests that NADH is insufficiently reoxidized by the ETC or that mitoNEET may enhance glycolytic rates (an NADH-generating process) to compensate for reduced β-oxidation. Notably, in parallel with the low OCRs in MitoN-Tg sWAT, we found concomitant higher glycolytic rates in MitoN-Tg compared to WT whole-tissue sWAT slices (as judged by a higher extracellular acidification rate (ECAR), an established indicator of glycolysis 32 ) (Supplementary Fig. 3 ). This high amount of glycolytic flux supports a model of a mitoNEET-driven shift in substrate utilization and metabolism from lipid-based substrates to carbohydrate-based substrates.
Defects in ETC activity have a marked impact on ROS production 31, 33 . After an oral gavage of 20% intralipid to create an environment of heightened lipid-stimulated ROS production within MitoN-Tg and WT sWAT, we assessed F2-isoprostane concentrations to gauge ROS-driven lipid peroxidation 19 . Notably, MitoN-Tg sWAT harbored substantially fewer products of ROS-induced lipid peroxidation than did WT sWAT (Fig. 4f) . Low ROS concentrations in mitoNEET-enriched fat pads are therefore a characteristic feature of mitoNEET-overexpressing adipocytes. To complement these biochemical assays, we focused on mitochondrial morphology. Electron microscopy analyses revealed that MitoN-Tg sWAT mitochondria are elongated and form long filamentous structures (Fig. 4g) . Moreover, these mitochondria are recurrently juxtaposed to lipid-droplet-like structures (Fig. 4g) , a phenomenon that has been observed in exercising skeletal-muscle mitochondria in response to increasing energy demand 34 . More mitochondria are visible per section of adipose tissue in MitoN-Tg than WT sWAT (Fig. 4g) , suggesting induction of mitochondrial biogenesis. The markedly higher peroxisome proliferatoractivated-γ coactivator 1-α (Pgc1-α) message levels in MitoN-Tg than WT sWAT (Fig. 2a) , a key regulator of mitochondrial biogenesis 35 , is consistent with this observation. Liver-specific overexpression of mitoNEET To examine an alternative, acute in vivo modality to induce mitoNEET overexpression in cells other than adipocytes, we generated a mouse, termed here the TRE-mitoNEET mouse (TRE-mitoN), in which the expression of mitoNEET was driven by a tetracycline-inducible promoter element (a tet-responsive element, or TRE). For this promoter element to be operational, the presence of the 'tet-on' transcription factor, rtTA, is required. We provided this factor in a hepatocytespecific manner through a mouse that harbors the rtTA component under the control of a ubiquitously active Rosa26 promoter; a transcriptional stop cassette flanked by two loxP sites prevents transcription of the rtTA gene. We activated hepatic expression with an albuminpromoter-driven Cre transgene. We achieved hepatocyte-specific, doxycycline (Dox)-inducible mitoNEET overexpression by exposing the TRE-mitoN mice to an albumin-promoter-driven Cre recombinase (Supplementary Fig. 4a ). After feeding mice Dox containing HFD (Dox-HFD), they attained a substantial and reliable threefold overexpression of mitoNEET protein (Supplementary Fig. 4b) . Using this method, we were able to show the usefulness of mitoNEET as a manipulator of mitochondrial activity in other cell types. Consistent with our model of mitoNEET overexpression in adipose tissue, a mitoNEET-driven augmentation in lipid storage was preserved in the livers of TRE-mitoN mice. Qualitatively, hepatic lipid droplets were more prevalent in TREmitoN mice than in WT mice ( Supplementary Fig. 4c) ; this reflects a decline in mitochondrial respiratory capacity in the former group (Supplementary Fig. 4d) . Collectively, this suggests a similar effect exerted by mitoNEET in a cell type that is distinct from adipocytes, indicating a common effect of mitoNEET on cellular physiology in different tissue types.
Diametrically opposed effects for lower mitoNEET expression
MitoNEET overexpression allowed us to effectively manipulate mitochondrial function. To examine whether we could manipulate mitochondrial activity in an opposite direction through a reduction in mitoNEET expression, we generated mice harboring a Dox-inducible shRNA knockdown construct for mitoNEET (shRNA-mitoN mice) ( Supplementary Fig. 5a ); this construct was effective in a majority of tissues, including adipose tissue and the liver (data not shown), thus creating a systemic inducible knockdown of mitoNEET. After feeding shRNA-mitoN mice a chow diet containing Dox (Dox-chow), we found a marked reduction in the amount of mitoNEET protein in their adipose tissue and liver (Supplementary Fig. 5b) , which are the two tissues we opted to focus on in our analysis. Initial observations revealed that during Dox-HFD feeding, shRNA-mitoN mice gained considerably less body weight than WT littermates (Fig. 5a) . Notably, despite having lower body weights, shRNA-mitoN mice had worse glucose tolerance than WT littermates (Fig. 5b) . Given that we effectively modulated the ETC with mitoNEET overexpression, we hypothesized that this deterioration in insulin sensitivity may arise from an intensified amount of oxidative-stress 33, 36 . Indeed, shRNA-mitoN mice harbored a high degree of hepatic ROS-induced npg protein damage (Fig. 5c) , as assessed by enhanced amounts of protein carbonylation, a measure that was previously established to gauge oxidative damage within a cell 37 . Consistent with this, antioxidant treatment of WT and shRNA-mitoN mouse embryonic fibroblasts (MEFs) or primary hepatocytes isolated from WT and shRNA-mitoN mice was able to reverse a palmitate-induced reduction in the amount of phosphorylated Akt (pAkt) (Supplementary Fig. 5c ), suggesting that the ROS-associated worsening in glucose tolerance may be alleviated through the use of antioxidant treatments to reverse the negative effect on insulin signaling. A histological examination of livers after Dox-HFD feeding revealed that shRNA-mitoN mice have less lipid accumulation in their livers than do WT mice (Fig. 5d) , suggesting a local augmentation in β-oxidation. When examining the ∆Ψm, we found substantially enhanced tetramethylrhodamine methyl ester (TMRM) staining in Dox-induced shRNA-mitoN MEFs compared to WT MEFs treated with or without Dox (Fig. 5e) . In terms of mitochondrial oxidative capacity, shRNAmitoN MEFs had significantly higher OCRs in response to palmitate than did WT MEFs (P < 0.001, n = 10) (Fig. 5f) , directly showing that a reduction in mitoNEET expression enhances β-oxidation. When assessing electron flow, hepatic mitochondria isolated from Dox-chow-fed shRNA-mitoN mice had markedly higher OCRs in response to pyruvate, malate, succinate and ascorbate than hepatic mitochondria from WT mice on the same diet (Fig. 5g) , indicating higher mitochondrial activity in the absence of mitoNEET regardless of the substrate source. In light of this result, a previous report that included a partial characterization of cardiac mitochondria isolated from a systemic constitutive mitoNEET knockout mouse showed reduced oxidative capacity 13 . It is unclear what leads to these differential effects; however, it is probable that the tissues used in these latter studies, which develop in the constitutive absence of mitoNEET, may have compensatory mechanisms that prevail under the assay conditions used.
All the readouts from our loss-of-function mice were diametrically opposed to the gain-of-function phenotypes that we found in the first part of the analysis. This suggests that there may be a similar underlying mechanism that affects mitochondrial activity over the entire range of differential mitoNEET expressions. In addition, we observed higher concentrations of mitochondrial iron with a low expression of mitoNEET in the shRNA-mitoN mice compared to WT mice (Fig. 5h) , consistent with a role of mitoNEET as a key factor in the regulation of mitochondrial iron content.
DISCUSSION
We have developed a new tool to specifically alter the amount of mitochondrial activity in adipocytes and hepatocytes. We took advantage of the properties of the mitochondrial protein mitoNEET, which allowed us to profoundly alter mitochondrial function and lipid homeostasis in a cell-type-specific manner, thereby altering wholebody insulin sensitivity. We found these effects in a complementary set of mouse models that involve multiple independent approaches to achieve alterations in mitoNEET expression within a physiological range. We used an adipose-specific transgenic model, an inducible tissue-specific overexpression system and an inducible constitutive knockdown of mitoNEET. The overexpression of mitoNEET allowed us to compromise mitochondrial function to disrupt the cellular energy balance, driving a decline in β-oxidation and causing a compensatory enhancement in cellular nutrient uptake. This triggered chronic adipose tissue expansion, and the mice in this model grew massively obese to a weight that was on par with, or substantially higher than, the maximum weight reported in the literature for Mus musculus. Despite their obesity, mitoNEET overexpression during high caloric intake resulted in system-wide improvements in insulin sensitivity, thereby providing a model of a metabolically healthy, obese state that minimizes lipotoxicity in tissues that are prone to store lipids during excess caloric intake (Fig. 6) , a phenomenon that is also observed clinically 38 . We focused our analysis primarily on adipose tissue; however, an upregulation and knockdown of mitoNEET causes profound mitochondrial alterations in hepatocytes, MEFs and 3T3-L1 fibroblasts, suggesting that the observations in adipocytes may apply to other cell types as well. Future assessments should reveal more systematically which cell types are particularly prone to regulation by mitoNEET and under what physiological conditions this regulation may be relevant. This may be a function of how much 'spare capacity' mitochondria have under a given physiological condition; in other words, whether they operate at a near maximal rate relative to the completely uncoupled state. It is likely that such mitochondria would be more markedly affected by subtle changes in mitochondrial iron metabolism.
Ectopic lipid accumulation is a major risk factor in the progression of insulin resistance 39 . Our mice with adipocyte-specific overexpression of mitoNEET have only minimal amounts of ectopic lipids, thereby preserving insulin sensitivity despite excess caloric intake. Figure 6 Proposed mechanism of mitoNEET action. Schematic representation of the intracellular involvement of mitoNEET in adipocyte physiology based on its ability to manipulate mitochondrial function. There are system-wide metabolic consequences arising from a mitoNEET-induced mitochondrial perturbation at the level of the adipocyte. MitoNEET affects mitochondrial iron content, which may contribute to the decline in β-oxidation, and enhances fatty acid uptake by signaling through Cd36. Compromised mitochondrial function therefore triggers a compensatory upregulation of adipogenesis, β-3 adrenergic signaling and mitochondrial biogenesis. The cellular decrease in mitochondrial activity further enhances lipid influx into the cell. The inability to use these lipids effectively in the mitochondria shunts surplus substrates into the triglyceride (TG) pool. Consequently, low β-oxidation rates, high Ppar-γ activity and increased adiponectin levels accompanied by excess lipid storage results in gross adipose tissue (AT) expansion. The ability to store massive amounts of lipids in the sWAT results in a highly beneficial system-wide improvement in whole-body insulin sensitivity with minimized lipotoxic effects in other tissues. β3AR, the receptor for the catecholamines. The mechanisms for partitioning lipid storage versus β-oxidation are not fully defined, particularly in the context of the adipocyte. A key phenotype in transgenic mice is their enhanced lipid uptake and storage into sWAT, suggesting that mitoNEET may contribute to adjusting the relative ratio of energy stored to energy burned by altering mitochondrial bioenergetics. Another key finding was that manipulation of β-oxidation at the level of the white adipocyte causes a profound net systemic contribution toward whole-body energy homeostasis. In our model, incomplete β-oxidation may increase the cellular pool of peroxisome proliferator-activated receptor γ (Ppar-γ) ligands. Both high amounts of Ppar-γ and increased adipogenesis in the transgenic setting are consistent with this possibility. Adiponectin is a 30-kDa protein secreted exclusively from adipocytes that exerts antidiabetic, anti-inflammatory and antiatherogenic properties 6, 7 . Adequate mitochondrial function and biogenesis are crucial determinants for the folding and secretion of adiponectin [40] [41] [42] ; therefore, one of our aims was to establish and strengthen the evidence for this relationship. Indeed, mitoNEET overexpression causes a substantial increase in the amount of adiponectin, both transcriptionally and post-transcriptionally in transgenic sWAT, prompting an increase in circulating adiponectin concentrations. This upregulation of adiponectin may also be central to the enhanced triglyceride clearance in mitoNEET transgenic mice, as this effect was blunted when we crossed mitoNEET-overexpressing mice into an adiponectin-null background. Taken together, the adipocyte-specific impairment in β-oxidation led to a substantial local increase in adiponectin production and release; this may be a valuable observation in the context of our teleological understanding of the function of adiponectin, which may serve to gauge the mitochondrial lipid demand in adipocytes. Adiponectin could therefore act as a powerful systemic signal to drive dietary and tissue lipids toward the adipocyte 5 . However, future studies will need to delineate the detailed mechanistic steps that connect compromised mitochondrial function with the paradoxical increase in adipocytederived adiponectin production.
The mitochondrial membrane potential (∆Ψm) is a crucial parameter that reflects ETC activity. Considerable loss or depolarization of ∆Ψm could lead to low cellular energy 43 , as cells with impaired oxidative phosphorylation have low ∆Ψm 44 . Overexpressing mitoNEET in 3T3-L1 preadipocytes lowers their ∆Ψm, indicating some degree of energy depletion. Therefore, either overabundance of mitoNEET (compromising mitochondrial function) or a reduction in the amount of mitoNEET (which has the potential for rapid cellular substrate depletion caused by excessive mitochondrial activity) may bring mitochondrial function out of sync with cellular energy requirements, accentuating that the amount of mitoNEET must be harmonized with intracellular energy demands. Alterations in mitoNEET expression further allowed us to manipulate ROS concentrations.
Heightened ROS generation results from severe alterations in oxidative metabolism 31 . Although ROS concentrations intensify with obesity 45 , a mitoNEET-induced increase in lipid uptake accompanied by low β-oxidation may alleviate the burden of flux through ROSproducing β-oxidation pathways, thereby protecting adipose tissue from ROS-induced oxidative injury. This paradox of low ROS generation in an oversized, lipid-laden fat pad implies a fully functional ROS-scavenging system. No mitochondrial dysfunction per se exists in a mitoNEETenriched environment; rather, there is an insufficient rate of ETC activity. Interestingly, ROS generation is greater when basal respiration is supported by fatty acids rather than carbohydrate-based substrates 46 . Low β-oxidation rates accompanied by high glycolytic rates caused by mitoNEET overexpression may further sustain low ROS production.
Oxidative stress is also a robust negative correlate of insulin sensitivity 33, 36, 47 . Despite gaining less body weight during HFD-feeding, mitoNEET knockdown mice have high amounts of ROS-induced protein damage and are less glucose tolerant. ROS generation is prominent when the proton motive force is large 48 ; for example, hyperglycemia-induced hyperpolarization elevates ROS production as a result of enhanced cellular respiration 49 . The high ∆Ψm after a reduction of mitoNEET expression, accompanied by enhanced oxygen-consumption rates, implicates that ROS may contribute to glucose intolerance. Indeed, other mouse models that are engineered to increase flux through β-oxidation pathways develop severe insulin resistance despite harboring protection from HFD-induced obesity 50 . Our in vitro results in this system confirmed that antioxidant treatment of cells with low expression of mitoNEET leads to improvements in cellular insulin signal transduction.
Two key regulators of ETC activity and ROS concentrations are the intracellular redox potential of NAD + and NADH, and the proton motive force. A surplus of the reduced equivalents NADH and FADH 2 , formed through glycolysis and the tricarboxylic acid cycle, are reoxidized through the ETC. Vice versa, a mismatch between β-oxidation and ETC activity disrupts the energy milieu of mitochondria by perturbing redox status 1 to reduce the ratio of NAD + to NADH. As an overexpression of mitoNEET lowers the NAD + : NADH ratio, a buildup of NADH implies that (i) compensatory high glycolytic rates may generate surplus NADH from the decline in β-oxidation, (ii) ETC activity is insufficient to reoxidize NADH, (iii) mitoNEET may affect NAD and NADH flux through various catabolic pathways or (iv) mitoNEET may alter NAD shuttle systems, salvage or degradation such that mitochondrial performance is further perturbed by rising NADH concentrations 1 .
Low mitochondrial iron content can decrease the activity of ironcontaining ETC complexes and enzymes to diminish respiratory activity 26 . An excess of mitoNEET causes reduced concentrations of mitochondrial iron, and vice versa, a reduction in the amount of mitoNEET causes an increase in iron concentrations and ETC activity. This pinpoints iron transport as one of the crucial aspects of mitoNEET function. Indeed, researchers from a recent study showed that iron overload (in the context of hereditary hemochromatosis) is associated with a shift from glucose to fatty acid oxidation and an increased risk of developing diabetes 28 . These observations are fully consistent with the findings reported here in which a downregulation of mitoNEET led to similar phenotypic manifestations.
In summary, we identify the mitochondrial protein mitoNEET as a valuable tool in energy homeostasis and lipid metabolism. We used mitoNEET as a genetic tool to manipulate ETC activity by taking advantage of its ability to exert control over mitochondrial iron availability. We show that within the adipocyte, mitoNEET compromises mitochondrial efficacy, triggers a massive nutrient influx into the cell, enhances adiponectin production and increases β-3 adrenergic sensitivity. The increased lipid influx, combined with reduced oxidative capacity, initiates massive adipose tissue expansion; despite the resulting obesity, insulin sensitivity is preserved. Several of these effects are probably dependent on a mitoNEET-mediated induction of adiponectin. Such mitoNEET-driven alterations in mitochondrial function therefore represent pivotal mechanisms that link obesity-related insulin resistance with mitochondrial perturbations and, further, open the door to effective manipulation of mitochondrial activity in additional cell types. Although a higher mitochondrial concentration of mitoNEET protein in adipocytes promotes further obesity, it also triggers enhanced adiponectin release and, thus, improved insulin sensitivity. The association of increased obesity with improvements in insulin sensitivity is counterintuitive. However, the obesity-associated toning down of mitochondrial activity could serve as an adaptive process in an attempt by cells to counter the effects of excess lipid intake. We therefore suggest that a moderate reduction in mitochondrial oxidative phosphorylation specifically in the sWAT fat pad paradoxically favors beneficial metabolic outcomes. MitoNEET drives an adipocyte to preferentially store lipids, concomitant with a decreased propensity to oxidize them. In particular, our bioenergetic profiling reveals that mitoNEET-overexpressing mitochondria have low oxygenconsumption rates in response to various substrates. In contrast, an environment deficient in mitoNEET enhances lipid-and carbohydratebased respiration. Taken together, we propose an inverse correlation between mitoNEET and oxidative capacity, a phenomenon that, when operational in the subcutaneous fat pad, drives an effective improvement in whole-body metabolism. To better understand the regulation of this process under normal physiological conditions, our future studies will focus on the regulation of endogenous mitoNEET and its detailed molecular mechanism of action. Furthermore, a better understanding of how altered energetic states of mitochondria affect adiponectin production, assembly and release deserves more attention in light of the potent metabolic improvements triggered by even moderate changes in cellular and plasma adiponectin concentrations.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The microarray data have been uploaded to the Gene Expression Omnibus database under accession code GSE39251.
quickly excised, weighed and frozen at −80 °C until processing. Lipids were then extracted using a chloroform-to-methanol based extraction method 58 . The radioactivity content of tissues, including blood samples, was quantified as described previously 57 .
Statistics. All results are provided as means ± s.e.m. All statistical analyses were performed using GraphPad Prism. Differences between the two groups over time (indicated in the relevant figure legends) were determined by a two-way analysis of variance for repeated measures. For comparisons between two independent groups, a Student's t test was used. Significance was accepted at P < 0.05.
